Investigators at the Johns Hopkins Kimmel Cancer Center and the Johns Hopkins Bloomberg School of Public Health have identified a…
Read More
Scientists Uncover How Gene Fusion Droplets Drive Rare Kidney Cancer Progression and Potential New Therapeutic Targets
In a significant breakthrough for oncology and molecular biology, a multidisciplinary team of investigators at the Johns Hopkins Kimmel Cancer…
Read More
Johns Hopkins Researchers Uncover Molecular Mechanism Driving Rare Kidney Cancer Progression through Liquid Protein Droplets
In a significant advancement for the field of precision oncology, a multidisciplinary team of investigators from the Johns Hopkins Kimmel…
Read More
Breakthrough in Rare Kidney Cancer Research Reveals How Gene Fusions Drive Tumor Progression via Liquid Condensates
In a significant advancement for the field of molecular oncology, a multi-disciplinary team of investigators from the Johns Hopkins Kimmel…
Read More
Scientists Identify Liquid Condensate Mechanism Driving Rare Kidney Cancer and Potential New Treatment Pathways
A collaborative research effort led by scientists at the Johns Hopkins Kimmel Cancer Center and the Johns Hopkins Bloomberg School…
Read More
Johns Hopkins Researchers Uncover Molecular Mechanism Driving Rare Translocation Kidney Cancer Through Liquid Condensate Formation
In a significant advancement for the field of oncology, investigators at the Johns Hopkins Kimmel Cancer Center and the Johns…
Read More
A Coordinated Medical Approach for Cardiovascular-Kidney-Metabolic Syndrome: A New Clinical Guideline
A landmark clinical guideline, published on June 9th in the esteemed journal Circulation, heralds a significant paradigm shift in the…
Read More
A Coordinated Medical Approach to Overlapping Cardiovascular, Kidney, and Metabolic Conditions Emerges in New Clinical Guideline
A groundbreaking clinical guideline published on June 9 in the esteemed journal Circulation heralds a significant shift in how prevalent…
Read More
Eli Lilly and Ascidian Therapeutics Forge Strategic Alliance to Pioneer Novel Genetic Medicines for Kidney Diseases
Eli Lilly and Company, a global pharmaceutical leader, has significantly bolstered its commitment to the cutting-edge field of genetic medicines…
Read More
Eli Lilly and Ascidian Therapeutics Forge Strategic Alliance to Revolutionize Kidney Disease Treatment Through Advanced Genetic Medicine
Eli Lilly and Company has announced a significant research collaboration and licensing agreement with Ascidian Therapeutics, a pioneering biotechnology firm…
Read MoreYOU MAY HAVE MISSED
